MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
14. Dezember 2022 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis Phase 2 study represents an important step in psoriatic arthritis...